Document:

SHARE
PURCHASE AND GENERAL RELEASE AGREEMENT

 

This
Share Purchase and General Release Agreement (“Agreement”) is entered into by and between Peter Taddeo (the
“Investor”) and Biotech Products Services and Research, Inc., a Nevada corporation (“BPSR”
or the “Company”), and Mint Organics, Inc., a Florida corporation and subsidiary of BPSR (“Mint Organics”
and together with BPSR, the “Company Entities”). Investor and each of the individual Company Entities are sometimes
referred to herein as a “Party” and collectively as the “Parties”. This Agreement is effective
on the date this Agreement has been executed by all the Parties (the “Effective Date”).

 

WHEREAS,
pursuant to that certain Participation Agreement, dated January 27, 2017 (the “Participation Agreement”), between
BPSR and the Investor, the Investor purchased 150 shares of Series A Convertible Preferred Stock, par value $0.001 per share (the
“Series A Preferred Stock”), of Mint Organics and a warrant exercisable for up to 150,000 shares of BPSR common
stock for $0.15 per share from the date of issuance until the third anniversary of the date of issuance (the “Warrant”)
for an aggregate purchase price or $150,000;

 

WHEREAS,
the Parties desire to enter into this Agreement whereby BPSR shall purchase the Investor’s Series A Preferred Stock pursuant
to the terms and conditions set forth herein;

 

WHEREAS,
the Parties also desire to enter into this Agreement for the purpose of resolving any and all obligations and/or differences,
which the Company Entities or Investor now have or in the future may have with respect to each other, and to settle and resolve
forever any and all alleged claims arising out of any Investor’s investment in the Company Entities;

 

NOW,
THEREFORE, in consideration of the mutual promises contained herein and other good and valuable consideration set forth in
this Agreement, the receipt of which is acknowledged, Investor and the Company Entities agree as follows:

 

ARTICLE
I

 

SHARE
PURCHASE AGREEMENT

 

Section
1.01 Purchase of Shares. Subject to the terms and conditions set forth herein, on the Effective Date of this Agreement,
BPSR shall purchase from Investor, and Investor shall sell to BPSR, Investor’s 150 shares (the “Shares”)
of Series A Preferred Stock (the “Share Purchase”) for an aggregate purchase price of $40,000 (the “Purchase
Price”). The Purchase Price shall be paid as follows; (a) $25,000 upon execution of this Agreement (“Initial
Payment Amount”), but no later than 3 days from the Effective Date, and $15,000 to be paid to Investor no later than
45 days from the effective date of this Agreement (“Future Payment Amount”). All payments made to the Investor
in connection with the Purchase Price will be made by wire transfer of immediately available funds to an account of the Investor
designated in writing by the Investor to BPSR. Immediately upon receipt of the Initial Payment Amount in full by Investor, Investor
shall deliver to BPSR one or more stock certificates evidencing the Shares, free and clear
of all Encumbrances (as defined herein), duly endorsed in blank or accompanied by stock powers or other instruments of transfer
duly executed in blank (the “Transaction Documents”).

 

    	 	 	 

    	 

    

 

ARTICLE
II

 

REPRESENTATIONS,
WARRANTIES AND COVENANTS

 

Section
2.01 Representations, Warranties and Covenants of the Company Entities. The Company Entities represent, warrant and
covenant to the Investor the following:

 

(a)
Due Organization; Good Standing. They are duly incorporated, validly existing and in good standing under the laws of the
state of their respective incorporation and have full corporate power and authority to enter into this Agreement, to carry out
their obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The execution and
delivery by them of this Agreement, the performance by them of their obligations hereunder and the consummation by them of the
transactions contemplated hereby have been duly authorized by all requisite corporate action on the part of such entities. This
Agreement has been duly executed and delivered by their respective board of directors, and (assuming due authorization, execution
and delivery by Investor ) this Agreement constitutes a legal, valid and binding obligation, enforceable against them in accordance
with its terms.

 

(b)
No Conflicts; Consents. The execution, delivery and performance
by the Company Entities of this Agreement, and the consummation of the transactions contemplated hereby, do not and will not require
the consent, notice or other action by any person under any Contract to which any of the Company Entities is a party. No consent,
approval, permit, governmental order, declaration or filing with, or notice to, any governmental authority is required by or with
respect to Investor in connection with the execution and delivery of this Agreement and the consummation of the transactions contemplated
hereby and thereby.

 

(c)
Brokers. No broker, finder or investment banker is entitled
to any brokerage, finder’s or other fee or commission in connection with the transactions contemplated by this Agreement
based upon arrangements made by or on behalf of any the Company Entities.

 

Section
2.02 Representations and Warranties of the Investor.

 

(a)
Authority of Investor. Investor has full power and authority
to enter into this Agreement and the other Transaction Documents to which Investor is a party, to carry out its obligations hereunder
and thereunder and to consummate the transactions contemplated hereby and thereby. This Agreement has been duly executed and delivered
by Investor , and (assuming due authorization, execution and delivery by the Company) this Agreement constitutes a legal, valid
and binding obligation of Investor enforceable against Investor in accordance with its terms. When each other Transaction Document
to which Investor is or will be a party has been duly executed and delivered by Investor (assuming due authorization, execution
and delivery by each other party thereto), such Transaction Document will constitute a legal and binding obligation of Investor
enforceable against it in accordance with its terms.

 

(b)
The Shares are owned of record and beneficially by Investor, free and clear of all liens, pledges, security interests, charges,
claims, encumbrances, agreements, options, voting trusts, proxies and other arrangements or restrictions of any kind (“Encumbrances”).

 

(c)
No Conflicts; Consents. The execution, delivery and performance
by Investor of this Agreement and the other Transaction Documents to which it is a party, and the consummation of the transactions
contemplated hereby and thereby, do not and will not require the consent, notice or other action by any Person under any Contract
to which Investor is a party. No consent, approval, Permit, Governmental Order, declaration or filing with, or notice to, any
Governmental Authority is required by or with respect to Investor in connection with the execution and delivery of this Agreement
and the other Transaction Documents and the consummation of the transactions contemplated hereby and thereby.

 

___
(Initials)

 

    	 2

    	 

    

 

(d)
Brokers. No broker, finder or investment banker is entitled
to any brokerage, finder’s or other fee or commission in connection with the transactions contemplated by this Agreement
or any other Transaction Document based upon arrangements made by or on behalf of Investor.

 

ARTICLE
III

 

RELEASE
OF CLAIMS

 

Section
3.01 Release of Company Group by Investor. Upon the full payment of the Purchase Price to Investor in accordance with
the terms herein, Investor, for himself, his heirs, executors, administrators and assigns (the “Investor Releasees”),
shall RELEASE, ACQUIT AND FOREVER DISCHARGE the Company Entities and their predecessors, successors, assigns, divisions, subsidiaries
parents, and affiliates (the “Company Group”), and each and all former, present and future officers, directors,
shareholders, members, investors, agents, and representatives of any member of the Company Group (all of whom are hereinafter
collectively referred to as “Releasees”) from any and all claims, demands and causes of action of any kind
or character, whether known or unknown, which Investor ever had, now has or may hereafter have against any of Releasees, arising
out of any act, omission, transaction or event occurring prior to or as of the Closing Date, including, without limitation, those
related to Investor’s investment into the Company Entities (the “Company Release”). Without limiting
the generality of the foregoing, it is understood and agreed that this release shall constitute and includes a release by Investor
Releasees from any and all claims, grievances, demands, charges, liabilities, obligations, actions, causes of action, damages,
costs, losses of services, expenses, and compensation of any nature whatsoever, whether based on tort, contract or other theory
of recovery, on account of, or in any way growing out of Investor’s involvement with or separation from the Company Entities.
Should the Company Entities breach any of their obligations under this Agreement, including payments of the Purchase Price amounts
as described herein, this release is void.

 

Section
3.02 Waiver. The Investor hereby acknowledges and agrees that the Company Release shall constitute a general release
against Releasees, and the Investor, for itself, himself, is heirs, executors, administrators and assigns, shall hereby expressly
waive and assume the risk of any and all claims for damages against any of Releasees that exist as of the date of this Agreement
but of which he does not know or suspect to exist, whether through ignorance, oversight, error, negligence, or otherwise, and
which, if known, would materially affect his decision to enter into this Agreement. Investor further hereby agrees that will be
accepting the payments provided herein as a full and complete compromise of any and all matters involving disputed issues of law
and fact against Releasees, and that he will assume the risk that the facts or law may be otherwise than he believes.

 

Section
3.03 Non-Disparagement Agreement.

 

(a)
The Investor hereby acknowledges and agrees that he has not, and will not, subsequent to the presentation and execution of this
Agreement, verbally or in writing, defame, disparage, deprecate, discredit, vilify, or make any statements to any third parties
that in any way may be considered harmful or negatively impact the Company Entities and their Investor officers, directors or
employees.

 

___
(Initials)

 

    	 3

    	 

    

 

(b)
The Company Entities hereby acknowledge and agree that they and any of their Investor officers and directors have not, and will
not, subsequent to the presentation and execution of this Agreement, verbally or in writing, defame, disparage, deprecate, discredit,
vilify, or make any statements to any third parties that in any way may be considered harmful or negatively impact the Investor.

 

ARTICLE
IV

 

MISCELLANEOUS

 

Section
4.01 Termination. This Agreement shall be terminated
immediately upon BPSR’s failure to make any of the Purchase Price payments within the deadlines prescribed in this Agreement.
Upon termination, all further obligations of the parties under this Agreement shall terminate
without liability of any party to the other parties to this Agreement, except that no such
termination shall relieve any party from liability for any fraud or willful breach of this Agreement.
If this Agreement is terminated due to BPSR’s failure to make any of the required Purchase Price payments, then the Investor
shall retain ownership of the Shares to provide for conversion as described below, and BPSR shall have no rights to purchase the
Shares, despite having already paid any amounts associated with the Purchase Price. 

 

Upon
such time that BPSR does not make and payments of the Purchase Price as required, then the Investor, immediately upon the effective
termination of this Agreement, shall have been deemed to have provided notice to BPSR to convert the Shares in accordance with
the terms of the Shares, and which BPSR agrees that any notice provision period for the conversion of the Shares will be automatically
extended to the extent necessary so that the Investor’s right to provide the above notice complies with the terms of the
Shares. BPSR shall immediately deliver a certificate
or confirmation from the transfer agent of BPSR’s Common Stock evidencing the shares of BPSR Common Stock issued in the
name of the Investor. The applicable conversion price of the
Shares shall be determined based on the average closing price of BPSR stock for the previous 10 trading days ending on the 45th
days from the Effective Date.

 

Rule
144. In the event BPSR converts the Shares into BPSR common stock as a result of termination, BPSR, based on its reasonable
judgment, financial condition and best efforts, shall seek to remain and/or regain in compliance with the public reporting requirements
of the U.S. Securities and Exchange Commission (“SEC”). BPSR shall further provide any reasonable customary information
requested by Investor or his brokerage firm in connection with Investor’s ownership of the BPSR common stock, and obtain
a legal opinion requested in connection with Investor’s efforts to sell such shares under Rule 144 of the Securities Act
or successor rule(s); provided that, Investor provides BPSR and its legal counsel with the necessary documentation needed to render
a legal opinion in connection with Rule 144 and BPSR and/or Investor have met the required conditions for such opinion to be issued.

 

Section
4.02 Standstill Agreement. Investor agrees that during the term of this Agreement, the
Investor will not be entitled to request BPSR to convert or purchase the Shares nor make any legal claim or threaten to make a
legal claim against any member of the Company Group. All prior notices for conversion of the Shares provided by Investor to BPSR
shall be withdrawn. 

 

Section
4.03 No Admission of Liability. Neither the execution of this Agreement, nor the performance of the consideration given
for this Agreement, shall constitute nor be deemed to be an admission of liability on the part of any Party hereto, all of which
is expressly denied.

 

___
(Initials)

 

    	 4

    	 

    

 

Section
4.04 Acknowledgments. Investor acknowledges that he is fully informed as to the terms, contents, conditions and effects
of this Agreement and that, in executing this Agreement, he does not rely and has not relied upon any representation (oral or
written) or statement made by the Company, any of its officers or directors or its attorneys, including, but not limited to, any
representation or statement with regard to the subject matter, basis, or effect of this Agreement. Investor further acknowledges
the following:

 

(a)
he has been advised to consult with an attorney of his choosing prior to executing this Agreement;

 

(b)
he is over the age of eighteen (18) years, of sound mind and otherwise competent to execute this Agreement; and

 

(c)
he is entering into this Agreement knowingly and voluntarily and without any undue influence or pressures.

 

Section
4.05 Attorneys’ Fees. The Parties acknowledge that any violation or threatened violation of any of the provisions
of this Agreement would constitute a material breach of this Agreement and that the prevailing Party shall be entitled to compensatory
damages, attorneys’ fees, costs, and such other and further relief to which the prevailing Party may show itself justly
entitled.

 

Section
4.06 Expenses.
All costs and expenses incurred in connection with this Agreement and each other agreement, document, and instrument contemplated
by this Agreement and the transactions contemplated hereby and thereby shall be paid by the party incurring such costs and expenses,
whether or not the Closing shall have occurred.

 

Section
4.07 Further Assurances.
Each of the Parties hereto shall execute and deliver such additional documents, instruments, conveyances, and assurances and take
such further actions as may be reasonably required to carry out the provisions hereof and give effect to the transactions contemplated
hereby.

 

Section
4.08 Public Announcements.
Unless otherwise required by applicable law (based upon the reasonable advice of counsel), no party to this Agreement shall make
any public announcements in respect of this Agreement or the transactions contemplated hereby or otherwise communicate with any
news media without the prior written consent of the other party and the parties shall cooperate as to the timing and contents
of any such announcement.

 

Section
4.09 Notices.
All notices, requests, consents, claims, demands, waivers, and other communications hereunder (each, a “Notice”)
shall be in writing and addressed to the parties at the addresses set forth on the signature page of this Agreement (or to such
other address that may be designated by the receiving party from time to time in accordance with this Section). All Notices shall
be delivered by personal delivery, nationally recognized overnight courier (with all fees pre-paid), facsimile or email (with
confirmation of transmission) or certified or registered mail (in each case, return receipt requested, postage pre-paid). Except
as otherwise provided in this Agreement, a Notice is effective only (a) upon receipt by the receiving party, and (b) if the party
giving the Notice has complied with the requirements of this Section.

 

Section
4.10 Interpretation.
For purposes of this Agreement, (a) the words “include,” “includes,” and “including” are deemed
to be followed by the words “without limitation;” (b) the word “or” is not exclusive; and (c) the words
“herein,” “hereof,” “hereby,” “hereto,” and “hereunder” refer to this
Agreement as a whole. Unless the context otherwise requires, references herein: (x) to sections, schedules, and exhibits mean
the sections of, and schedules and exhibits attached to, this Agreement; (y) to an agreement, instrument, or other document means
such agreement, instrument, or other document as amended, supplemented, and modified from time to time to the extent permitted
by the provisions thereof; and (z) to a statute means such statute as amended from time to time and includes any successor legislation
thereto and any regulations promulgated thereunder. This Agreement shall be construed without regard to any presumption or rule
requiring construction or interpretation against the party drafting an instrument or causing any instrument to be drafted. The
schedules and exhibits referred to herein shall be construed with, and as an integral part of, this Agreement to the same extent
as if they were set forth verbatim herein.

 

___
(Initials)

 

    	 5

    	 

    

 

Section
4.11 Headings.
The headings in this Agreement are for reference only and shall not affect the interpretation of this Agreement.

 

Section
4.12 Severability.
If any term or provision of this Agreement is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality,
or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such
term or provision in any other jurisdiction. Upon such determination that any term or other provision is invalid, illegal, or
unenforceable, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of
the parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated
as originally contemplated to the greatest extent possible.

 

Section
4.13 Entire Agreement.
This Agreement any other documents incorporated herein by reference constitutes the sole and entire agreement of the parties to
this Agreement with respect to the subject matter contained herein and supersedes all prior and contemporaneous understandings,
agreements, representations, and warranties, both written and oral, with respect to such subject matter

 

Section
4.14 Amendment and Modification.
This Agreement may only be amended, modified, or supplemented by an agreement in writing signed by each party hereto.

 

Section
4.15 Waiver.
No waiver by any party of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by
the party so waiving. No waiver by any party shall operate or be construed as a waiver in respect of any failure, breach, or default
not expressly identified by such written waiver, whether of a similar or different character, and whether occurring before or
after that waiver. No failure to exercise, or delay in exercising, any right, remedy, power, or privilege arising from this Agreement
shall operate or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power, or privilege
hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power, or privilege.

 

Section
4.16 Assignment.
Neither party may assign any of its rights or delegate any of its obligations hereunder without the prior written consent of the
other party, which consent shall not be unreasonably withheld, conditioned, or delayed. Any purported assignment or delegation
in violation of this Section shall be null and void. No assignment or delegation shall relieve the assigning or delegating party
of any of its obligations hereunder.

 

Section
4.17 Successors and
Assigns. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective
successors and permitted assigns.

 

Section
4.18 No Third-Party
Beneficiaries. This Agreement is for the sole benefit of the parties hereto and their respective successors and permitted
assigns and nothing herein, express or implied, is intended to or shall confer upon any other person or entity any legal or equitable
right, benefit, or remedy of any nature whatsoever under or by reason of this Agreement.

 

___
(Initials)

 

    	 6

    	 

    

 

Section
4.19 Governing Law.
All matters arising out of or relating to this Agreement shall be governed by and construed in accordance with the internal laws
of the State of Florida without giving effect to any choice or conflict of law provision or rule (whether of the State of Florida
or any other jurisdiction).

 

Section
4.20 Submission to Jurisdiction.
Any legal suit, action, or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby or
shall be instituted in the federal courts of the United States of America or the courts of the State of Florida in each case located
in the City of Miami, and County of Miami-Dade, and each party irrevocably submits to the exclusive jurisdiction of such courts
in any such suit, action, or proceeding. The parties irrevocably and unconditionally waive any objection to venue of any suit,
action, or proceeding in such courts and irrevocably waive and agree not to plead or claim in any such
court that any such suit, action, or proceeding brought in any such court has been brought in an inconvenient forum.

 

Section
4.21 Waiver of Jury Trial. Each
party acknowledges and agrees that any controversy that may arise under this Agreement is likely to involve complicated and difficult
issues and, therefore, each such party irrevocably and unconditionally waives any right it may have to a trial by jury in respect
of any legal action arising out of or relating to this Agreement or the transactions contemplated hereby.

 

Section
4.22 Counterparts.
This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be
deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, email or other means of electronic
transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

 

Section
4.23 Force Majeure.
No party shall be liable or responsible to the other party, nor be deemed to have defaulted under or breached this Agreement,
for any failure or delay in fulfilling or performing any term of this Agreement (except for any obligations to make payments to
the other party hereunder), when and to the extent such failure or delay is caused by or results from acts beyond the affected
party’s reasonable control, including, without limitation: (a) acts of God; (b) flood, fire, earthquake, or explosion; (c)
war, invasion, hostilities (whether war is declared or not), terrorist threats or acts, riot, or other civil unrest; (d) government
order or law; (e) actions, embargoes, or blockades in effect on or after the date of this Agreement; (f) action by any governmental
authority; and (g) national or regional emergency. The party suffering a Force Majeure Event shall give notice within 3 days of
the Force Majeure Event to the other party, stating the period of time the occurrence is expected to continue and shall use diligent
efforts to end the failure or delay and ensure the effects of such Force Majeure Event are minimized.

 

Section
4.24 Business Days.
If any date on which a party is required to make a payment or a delivery pursuant to the terms hereof is not a Business Day, then
such party shall make such payment or delivery on the next succeeding Business Day.

 

[SIGNATURE
PAGE FOLLOWS]

 

___
(Initials)

 

    	 7

    	 

    

 

IN
WITNESS WHEREOF, the Parties have executed this Agreement intending to be fully legally bound.

 

	 	BIOTECH
    PRODUCTS SERVICES AND RESEARCH, INC.
	 	 	 
	Date:
    April 6, 2018	By:	/s/
    Albert Mitrani 
	 	Name:	Albert
    Mitrani
	 	Title:	Chief
    Executive Officer
	 	 	 
	 	MINT
    ORGANICS, INC.
	 	 	 
	Date:
    April 6, 2018	By:	/s/
    Ian Bothwell 
	 	Name:	Ian
    Bothwell
	 	Title:	Chief
    Financial Officer
	 	 	 
	Date:
    April 6, 2018	By:	/s/
    Peter Taddeo
	 	 	PETER
    TADDEO

 

___
(Initials)

 

    	 8AMENDMENT
NO. 2 TO EMPLOYMENT AGREEMENT

 

This
Amendment No. 2 to Employment Agreement, dated as of April 6, 2018 (the “Amendment”), by and between Ian T.
Bothwell (the “Executive”) and Biotech Products Services and Research, Inc., a Nevada corporation (the “Company”
and together with the Executive, the “Parties”, and each, a “Party”).

 

WHEREAS,
the Parties have entered into that certain Employment Agreement, dated as of November 4, 2016 (the “Employment Agreement”);

 

WHEREAS,
the Employment Agreement was amended pursuant to Amendment No. 1, dated March 8, 2017;

 

WHEREAS,
the Parties hereto desire to again amend the Employment Agreement pursuant to this Amendment on the terms and subject to the conditions
set forth herein;

 

WHEREAS,
pursuant to Section 18 of the Employment Agreement, the amendment contemplated by the Parties must be contained in a written agreement
signed by each Party.

 

NOW,
THEREFORE, in consideration of the premises set forth above and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Parties agree as follows:

 

1.
Definitions. Capitalized terms used and not defined in this Amendment have the respective meanings assigned to them in
the Employment Agreement.

 

2.
Amendments to the Employment Agreement. As of the Effective Date (defined below), the Employment Agreement, as amended,
is hereby further amended or modified as follows:

 

(a)
Section 1 of the Employment Agreement shall be replaced in its entirety by the following:

 

Term.
The Executive’s employment hereunder shall be effective as of the Effective Date and shall continue until the fifth anniversary
thereof, unless terminated earlier pursuant to Section 5 of this Agreement; provided that, on such fifth anniversary of the
Effective Date and each annual anniversary thereafter (such date and each annual anniversary thereof, a “Renewal Date”),
the Agreement shall be deemed to be automatically extended, upon the same terms and conditions, for successive periods of five
years, unless either party provides written notice of its intention not to extend the term of the Agreement at least 90 days’
prior to the applicable Renewal Date. The period during which the Executive is employed by the Company hereunder is hereinafter
referred to as the “Employment Term”.

 

    	 

     

    

 

(b)
The following shall be added to Section 4.4(a) of the Employment Agreement:

 

(iii)
Notwithstanding any provision contained in this Agreement, in the event of an occurrence of a Change in Control (as defined in
Section 5.4(c)) or termination of the Agreement pursuant to Section 5.2 and/or Section 5.3, the exercise price for all outstanding
warrants granted to Executive to purchase common stock of the Company during the term of this Agreement shall be reduced to $0.001
per share.

 

(c)
Section 4.5(b) of the Employment Agreement shall be replaced in its entirety by the following:

 

An
automobile expense allowance of $2,500 per month plus all expenses related to the maintenance, repair and operation of such automobile
including, but not limited to, gas, oil and insurance premiums.

 

(d)
Section 4.5(c) of the Employment Agreement shall be replaced in its entirety by the following:

 

Reimbursement
for Rover related office rent and other direct expenses (phone, internet, copier, and direct administrative fees, etc.).

 

(e)
Section 5.2(a) of the Employment Agreement shall be replaced in its entirety by the following:

 

continued
Base Salary for the greater of (i) the remaining portion of the Employment Term or (ii) three years following the Termination
Date payable in equal monthly installments in accordance with the Company’s normal payroll practices, but no less frequently
than monthly; provided that, the first installment payment shall include all amounts of Base Salary that would otherwise
have been paid to the Executive during the period beginning on the Termination Date and ending on the first payment date if no
delay had been imposed;

 

    	2

     

    

 

(f)
Section 5.1(xiii) of the Employment Agreement which states that the termination of Bruce Werber from the Company shall
constitute “Good Cause” is hereby deleted in its entirety.

 

(g)
Section 5.4(a)(i) of the Employment Agreement shall be replaced in its entirety by the following:

 

a
lump sum payment equal to five (5) times the sum of the Executive’s Base Salary and Target Bonus for the year in which the
Termination Date occurs (or if greater, the year immediately preceding the year in which the Change in Control occurs), which
shall be paid within 50 days following the Termination Date; and

 

(h)
Section 5.4(b)(i) of the Employment Agreement shall be replaced in its entirety by the following:

 

all
outstanding unvested stock options and warrants granted to the Executive during the Employment Term shall become fully vested
and exercisable for the remainder of their full term and the exercise price of any such options and warrants shall be reduced
to par value ($0.001) per share;

 

3.
Date of Effectiveness; Limited Effect. This Amendment will be deemed effective as of the date first written above, subject
to the approval of the Board of Directors of the Company (the “Effective Date”). Except as expressly provided
in this Amendment, all of the terms and provisions of the Employment Agreement are and will remain in full force and effect and
are hereby ratified and confirmed by the Parties. Without limiting the generality of the foregoing, the amendments contained herein
will not be construed as an amendment to or waiver of any other provision of the Employment Agreement or as a waiver of or consent
to any further or future action on the part of either Party that would require the waiver or consent of the other Party. On and
after the Effective Date, each reference in the Employment Agreement to “this Agreement,” “the Agreement,”
“hereunder,” “hereof,” “herein” or words of like import, and each reference to the Employment
Agreement in any other agreements, documents or instruments executed and delivered pursuant to, or in connection with, the Employment
Agreement, will mean and be a reference to the Employment Agreement as amended by this Amendment.

 

4.
Miscellaneous.

 

(a)
This Amendment is governed by, and construed in accordance with, the laws of the State of Florida, without regard to the conflict
of laws provisions of such State.

 

(b)
This Amendment shall inure to the benefit of and be binding upon each of the Parties and each of their respective permitted successors
and permitted assigns.

 

(c)
The headings in this Amendment are for reference only and do not affect the interpretation of this Amendment.

 

(d)
This Amendment may be executed in counterparts, each of which is deemed an original, but all of which constitutes one and the
same agreement. Delivery of an executed counterpart of this Amendment electronically or by facsimile shall be effective as delivery
of an original executed counterpart of this Amendment.

 

(e)
This Amendment constitutes the sole and entire agreement of the Parties with respect to the subject matter contained herein, and
supersedes all prior and contemporaneous understandings, agreements, representations and warranties, both written and oral, with
respect to such subject matter.

 

SIGNATURE
PAGE FOLLOWS

 

    	3

     

    

 

IN
WITNESS WHEREOF, the Parties have executed this Amendment as of the date first written above.

 

	 	COMPANY:
	 	 	 
	 	BIOTECH
    PRODUCTS SERVICES AND RESEARCH, INC. 
	 	 
	 	By	/s/
    Albert Mitrani 
	 	Name:
    	Albert
    Mitrani
	 	Title:
    	CEO
    and President

 

	 	EXECUTIVE:
    
	 	 	 
	 	By
    	/s/
    Ian T. Bothwell 
	 	Name:
    	Ian
    T. Bothwell 

 

    	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00282-of-00352.parquet"}]]